Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02144350 · ClinicalTrials.gov registry record · Phase 2

Hyperbaric Oxygen for Ulcerative Colitis

A Phase 2 study, sponsored by Dartmouth-Hitchcock Medical Center.

Terminated
Registry status
Phase 2
Development phase
18
Enrollment target

NCT02144350 is a Phase 2 study that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02144350, a Phase 2 study, was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.

TERMINATED
Registry status
Phase 2
Development phase
18 participants
Enrollment target

Study Summary

The investigators aim to prospectively study the feasibility and clinical impact of hyperbaric oxygen therapy in acute hospitalized moderate to severe ulcerative colitis flares as an adjunct to standard medical treatment. Specifically, we will investigate the impact of hyperbaric oxygen therapy on clinical response/remission and serum and mucosal inflammatory markers. The investigators expect that hyperbaric oxygen therapy will improve patient responsiveness to steroids and avoid progression to second line therapy during hospitalization.

Interventions

  • PROCEDURE Hyperbaric oxygen
  • PROCEDURE Sham Hyperbaric Air

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2013-08
Est. Completion 2016-11
Phase Phase 2

Sponsor

Dartmouth-Hitchcock Medical Center

427 total trials

What the Registry Record Tells You About NCT02144350

The ClinicalTrials.gov registry entry for NCT02144350 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Hyperbaric oxygen is the first listed.

NCT02144350 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02144350 about?

NCT02144350 is a clinical study titled "Hyperbaric Oxygen for Ulcerative Colitis". The investigators aim to prospectively study the feasibility and clinical impact of hyperbaric oxygen therapy in acute hospitalized moderate to severe ulcerative colitis flares as an adjunct to standard medical treatment. Specifically, we will investigate the impact of hyperbaric oxygen therapy on c...

What is the current status of trial NCT02144350?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2013-08. Estimated completion is 2016-11.

What interventions are being tested in trial NCT02144350?

The interventions under investigation include: Hyperbaric oxygen (PROCEDURE), Sham Hyperbaric Air (PROCEDURE).

Who is sponsoring clinical trial NCT02144350?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.